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RNA-Mediated Neurodegeneration in
Repeat Expansion Disorders
Peter K. Todd, MD, PhD and Henry L. Paulson, MD, PhD
Most neurodegenerative disorders are thought to result primarily from the accumulation of misfolded proteins,
which interfere with protein homeostasis in neurons. For a subset of diseases, however, noncoding regions of
RNAs assume a primary toxic gain-of-function, leading to degeneration in many tissues, including the nervous
system. Here we review a series of proposed mechanisms by which noncoding repeat expansions give rise to
nervous system degeneration and dysfunction. These mechanisms include transcriptional alterations and the gen-
eration of antisense transcripts, sequestration of mRNA-associated protein complexes that lead to aberrant mRNA
splicing and processing, and alterations in cellular processes, including activation of abnormal signaling cascades
and failure of protein quality control pathways. We place these potential mechanisms in the context of known
RNA-mediated disorders, including the myotonic dystrophies and fragile X tremor ataxia syndrome, and discuss
recent results suggesting that mRNA toxicity may also play a role in some presumably protein-mediated neuro-
degenerative disorders. Lastly, we comment on recent progress in therapeutic development for these RNA-
dominant diseases.
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Nucleotide repeat expansion disorders comprise a het-erogeneous group of diseases that result from expan-
sion of specific repetitive DNA microsatellite sequences.
Pathogenic expansions can occur in coding or noncoding
regions of genes, and were initially believed to act in 2
dichotomous ways. In disorders such as Friedreich ataxia,
expansions in noncoding regions cause transcriptional si-
lencing or downregulation of the associated gene, and
therefore act as recessively inherited, loss-of-function mu-
tations. In contrast, in disorders such as Huntington dis-
ease, trinucleotide expansions in the protein coding region
introduce an abnormally long stretch of a single amino
acid (often glutamine) into the associated protein, which
leads to a dominantly inherited, gain-of function muta-
tion. In the 9 known polyglutamine diseases, the mutant
proteins accumulate in ubiquitin-positive inclusions and
interfere with cellular homeostasis through several differ-
ent mechanisms (for a recent review, see Williams and
Paulson1).
Many nucleotide repeat expansion disorders, how-
ever, do not fit neatly into either category. In myotonic
dystrophy (DM1), an expanded CTG repeat sequence in
the 3 untranslated region (UTR) of DMPK causes disease
in a dominantly inherited manner. After studies failed to
reveal a significant role for DMPK haploinsufficiency in
DM1 disease pathogenesis, evidence emerged supporting
a toxic gain of function mechanism at the RNA level.
Over the past 10 years, at least 7 other neurological dis-
orders have been identified that likely share this new
pathogenic mechanism, each with its own nuances (Table
and recent reviews2–5). This review addresses how these
nucleotide repeat expansions are thought to cause toxicity
and dysfunction by affecting (1) transcriptional regula-
tion, (2) mRNA splicing and metabolism, (3) RNA-
binding protein distribution, and (4) signal transduction
and cellular homeostatic pathways, with an eye toward
potential sites of therapeutic intervention.
A Primer on RNA Processing in
Neurologic Disease
To explain how repeat expansions in a noncoding region
of mRNA can lead to a multisystemic disease and neuro-
nal dysfunction, it is important that we first review recent
advances in understanding how RNA participates in gene
regulation, RNA processing, and protein translation. The
human transcriptome is made up of protein-coding
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mRNA and multiple different classes of noncoding
RNAs, including ribosomal RNAs, transfer RNAs, small
nuclear and nucleolar RNAs, microRNAs, and a host of
recently described RNA species whose functions are less
clear (eg, vault RNAs, Y RNAs, piwi-interacting RNAs,
large intervening noncoding RNAs; see Cooper et al4 for
a detailed review). Furthermore, many genes are tran-
scribed in both the sense direction (yielding a protein-
encoding mRNA) and the antisense direction (usually
producing a shorter noncoding sequence), often such that
increased production of the sense transcript is associated
with similar increases in the antisense transcript. The roles
of antisense transcripts are still incompletely defined, but
likely include regulation of transcription, stability, and
translation of the sense mRNA.
Messenger RNAs are initially transcribed as pre-
mRNAs that contain a 5UTR, a 3UTR, and numerous
noncoding intronic regions (introns) between the protein-
coding regions of the mRNA (exons). A pre-mRNA is
then spliced such that introns are removed, and a variable
subset of exons are compiled into a single linear sequence
for translation. For each pre-mRNA, usually multiple al-
ternatively spliced mature mRNAs are produced, with dif-
ferent mature mRNAs being favored in different tissue
and cell types or in response to different environmental
cues. The mature mRNA, still containing the 5UTR and
TABLE 1: RNA Mediated Neurological Disorders


















DM1: mental retardation in
50%
DM2 CCTG Intron 1 of
ZNF9
Up to 30 75-11,000 Unknown Neuropsychiatric symptoms
common; no congenital
onset or mental retardation













SCA3* CAG Exon 10 of
ATXN3

















SCA10 ATTCT 3UTR of
E46L






Up to 32 51-78 Unknown Action tremor; cerebellar
ataxia; dementia uncommon
HDL2 CTG 3UTR of
JPH-3





*  Proposed based on work in drosophila. Role of SCA3 RNA in mammalian models and patients is unknown.
CNS  central nervous system; DM1  myotonic dystrophy type 1; DMPK  dystrophin myotonica protein kinase; ORF 
open reading frame; DM2  myotonic dystrophy type 2; ZNF9  zinc finger 9; FXTAS  fragile X tremor ataxia syndrome;
UTR  untranslated region; FMR1  fragile X mental retardation gene 1; SCA  spinocerebellar ataxia; ATXN3  ataxin-3;
KLH1  Kelch-like 1; PPP2R2B  protein phosphatase 2, regulatory subunit B, beta isoform; HDL-2  Huntington disease-
like 2; JPH-3  junctophilin 3.
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3UTR, is then transported from the nucleus to the cy-
toplasm as part of a large ribonucleoprotein complex
known as an RNP. In the cytoplasm, it associates with
ribosomal components and is translated in a regulated
fashion. From the beginning of transcription through
splicing and translation, the mRNA is associated with nu-
merous RNA binding proteins and noncoding RNAs that
regulate its processing, stability, transport, and translation.
Both the coding and noncoding RNAs and their as-
sociated binding proteins are involved in numerous cellu-
lar pathways. These pathways, which include RNA pro-
cessing and the regulation of transcription and translation,
are critical determinants of neuronal differentiation and
plasticity. Perhaps not surprisingly, alterations in these
pathways have now been identified that contribute to a
wide variety of neurologic and non-neurologic disorders,
including a number of neurodegenerative diseases.4 For
example, mutations in two RNA-binding proteins in-
volved in RNA splicing, the Tar DNA-binding protein of
43kd (TDP-43) and fused in sarcoma (FUS), can cause
amyotrophic lateral sclerosis (ALS). Redistribution of
TDP-43 from the nucleus into cytoplasmic aggregates is a
common feature in sporadic ALS and frontotemporal de-
mentia.6
The RNA-dominant disorders discussed in this re-
view can result from expansions of repetitive sequences in
the 5UTR, the 3UTR, or intronic sequences of protein-
encoding mRNAs and can also occur as microsatellite ex-
pansions in nonprotein coding RNAs. In many cases, ev-
idence suggests the repeats are transcribed in both the
sense and antisense directions. Once transcribed, the pre-
mRNA containing these repeat expansions forms complex
secondary structures, including hairpin loops that can al-
ter their processing, transport, translation, and interac-
tions with RNA-binding proteins. In many cases, these
expanded repeat-containing RNAs accumulate and form
aggregates with a subset of RNA-binding proteins impli-
cated in regulating RNA splicing and transcription. To
date, most work in this field has focused on the concept
that formation of these nuclear aggregates, termed RNA
foci, drives pathogenesis via sequestration of specific
RNA-binding proteins. The relative absence of the RNA-
binding proteins then leads to misregulated processing of
numerous other non–repeat-containing RNA transcripts,
resulting in altered patterns of mRNA splicing and hence
alterations in protein isoform frequency. This sequestra-
tion hypothesis can explain many, but not all aspects, of
neurodegeneration in these disorders (Fig 1).
The Sequestration Hypothesis of RNA Toxicity
The most compelling evidence that sequestration of
RNA-interacting proteins by the expanded repeat-
containing mRNA causes neurological disease comes from
cellular and animal models of DM1 and pathological
FIGURE 1: The sequestration hypothesis of RNA-dominant disorders. Noncoding nucleotide repeat expansions can elicit
cellular dysfunction in many tissues, including the nervous system. (A) Under normal conditions, numerous RNA binding
proteins are involved in RNA splicing and processing, as well as in other cellular functions. (B) Expanded nucleotide repeat
sequences in RNA induce secondary hairpin structures that bind to and sequester numerous RNA-binding proteins, including
splicing factors (red circles), as well as factors involved in transcription and RNA trafficking (represented by green triangles).
The sequestration of these factors by the toxic RNA prevents the normal splicing and processing of other mRNAs, leading
to retention of rare splice isoforms. These isoforms are either less stable and thus rapidly degraded, or they encode
proteins with different functional characteristics from the major isoforms usually produced. In the central nervous system,
splicing errors can also interfere with proper distribution of the mRNA within neurons, especially dendrites.
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samples from patients with type I and type II myotonic
dystrophy. The following has been established:
• An expanded CTG repeat placed into the 3UTR of
an unrelated gene is sufficient to induce toxicity in
mouse and drosophila models, reproducing many as-
pects of the human disease.7,8
• In DM1 patients and various model systems, CUG
repeat-containing mRNA forms aberrant RNA foci in
the nucleus.9 These mRNA foci contain members of
the muscleblind-like family of RNA splicing proteins,
MBNL1, 2, and 3,10 and disrupt their normal nu-
clear distribution.
• Overexpression of MBNL1 in drosophila and mouse
models rescues the CTG repeat-induced muscle phe-
notype, and MBNL1 knockout mice recapitulate key
aspects of the adult form of the human disease, sug-
gesting that reduced MBNL1 splicing activity con-
tributes directly to DM1 pathophysiology.11,12
• Consistent with a major role for MBNL proteins in
DM1 pathogenesis, aberrant splicing occurs in several
key genes in DM1 muscle and brain.5
Perhaps the most convincing evidence for a primary
role of MBNL sequestration in DM1 RNA pathogenesis
came when the genetic cause for myotonic dystrophy type
2 was found to be another noncoding nucleotide expan-
sion in an unrelated gene, zinc finger 9. This expanded
CCUG repeat-containing RNA sequesters MBNL1 pro-
teins in the nucleus in RNA foci that are very similar to
those seen in DM1. Moreover, many of the same mis-
splicing events are shared between these two clinically
similar disorders.13
The sequestration model for RNA pathogenesis is
not limited to CUG/CCUG repeat expansions. It may
also apply to fragile X tremor ataxia syndrome (FXTAS),
a recently described cause of late onset dementia gait dis-
order and tremor that potentially affects upwards of
1:3,000 males.14 FXTAS is caused by an expanded CGG
repeat in the 5UTR of the FMR-1 gene on the X chro-
mosome. Normally, the sequence is 50 CGG repeats.
Expansion to 200 CGG repeats (a full mutation) leads
to transcriptional silencing of the FMR-1 gene and causes
fragile X syndrome, the most common inherited cause of
mental retardation. By contrast, patients with FXTAS
have a repeat between 50 and 200 CGG repeats. This
premutation range repeat is transcribed efficiently, and
there is near-normal expression of the fragile X mental
retardation protein, FMRP. Intriguingly, the translational
efficiency of a premutation CGG repeat mRNA is actu-
ally quite poor, but is offset by a 5- to 8-fold increase in
FMR1 mRNA levels.15,16
Pathologically, FXTAS is associated with neurode-
generation throughout the cortex and cerebellum. In ad-
dition, ubiquitin-positive inclusions accumulate in neuro-
nal and glial nuclei in these brain regions. These
inclusions contain the expanded FMR1 mRNA as well as
a host of proteins. Experimental evidence now suggests
that two RNA-binding proteins, Pur  and hnRNPA2/
B1, are sequestered to a degree that impairs their func-
tion.17,18 Pur  is a ubiquitously expressed RNA- and
DNA-binding protein that binds avidly to expanded
rCGG repeats in vitro and in vivo. Moreover, Pur  lo-
calizes to inclusions in the drosophila model of FXTAS
and, when overexpressed, mitigates CGG repeat-mediated
neurodegeneration. Similarly, hnRNPA2/B1, interacts di-
rectly with rCGG repeats and may act to recruit the
CUG-binding protein 1 (CUGBP1) into RNA inclu-
sions.18 Both CUGBP1 and hnRNP A2/B1 play multiple
roles in RNA processing, including RNA splicing, and
CUGBP1 has been implicated in the splicing abnormali-
ties in myotonic dystrophy (see below).19,20 In support of
a role for these two molecules in FXTAS, overexpression
of either hnRNP A2/B1 or CUGBP1 in a drosophila FX-
TAS model rescues the phenotype.18
Abnormal Activation of Signaling Cascades
Sequestration of MBNL into nuclear foci by CTG repeats
does not explain certain aspects of the phenotype in myo-
tonic dystrophy. In addition to the role of MBNL pro-
teins, there appears to be accumulation and aberrant sub-
cellular distribution of another splicing regulatory protein
family typified by the CUG-binding protein, CUGBP1.
This protein binds CUG RNA sequences, but is not
present in CUG RNA nuclear foci. Overexpression of
CUGBP1 recapitulates key features of the human disease,
and its induction may contribute to muscular atrophy and
aberrant differentiation in certain animal models of
DM1.21,22 The toxic consequences of CUGBP1 redistri-
bution are presumably mediated through altered splicing
of a different set of mRNAs than those targeted by
MBNL proteins.19 CUGBP1 is also known to impact
translational regulation, and thus its effects may be more
pleotropic.23
CUGBP1 is stabilized via phosphorylation by pro-
tein kinase C and is hyperphosphorylated in DM1 patient
tissues and in some animal models of DM1.24 Precisely
how an expanded CUG repeat leads to this phosphoryla-
tion is unknown. Some evidence suggests that expanded
nucleotide repeats can activate protein kinase cascades by
forming hairpin loops that trigger double-stranded RNA-
dependent protein kinase.25 How important such signal-
ing pathways are in other RNA-mediated disorders re-
mains to be seen, but overexpression of CUGBP actually
rescued CGG repeat dependent toxicity in a drosophila
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model of FXTAS, the opposite of the predicted effects in
DM1. Thus, the relevant signaling pathways may be af-
fected differently in each disorder.
Aberrant mRNA Splicing
The mis-spliced mRNAs in DM1 offer insight into how a
multisystemic disease can arise from a single noncoding
mutation. For example, misregulated splicing of ClC-1, a
chloride channel, leads to decreased expression of the ma-
ture channel in muscle fibers.20,26 This results in the mus-
cle hyperexcitability underlying myotonia. Importantly,
correction of the CIC-1 mis-splicing event alleviates the
myotonia in mouse models of DM1.27 Mis-splicing
events may also contribute to cardiac abnormalities and
muscle wasting seen in DM1.
Less is known about which mis-splicing events
might underlie central nervous system dysfunction in
DM1. To date, screens of a limited number of candidate
genes have identified 3 mis-spliced genes in the brains of
adult DM1 patients: abnormal splicing of exon 5 in glu-
tamate receptor NMDAR1, multiple exons in
microtubule-associated protein tau (MAPT), and exon 7
in the amyloid precursor protein (APP).28 These same
mis-splicing events were recently reported in a mouse
model of DM1.29 Of these 3, evidence best supports a
direct role for MAPT mis-splicing in the clinical symp-
toms of patients. There is accumulation of neurofibrillary
tangles and intranuclear inclusions that contain tau in
adult DM1 brains at autopsy, suggesting that DM1 is
partly a neurodegenerative disorder.30 In addition, both
APP and NMDAR1 are critically involved in synaptic
plasticity and neuronal function, and thus their mis-
splicing may explain some of the cognitive symptoms seen
in DM1, especially in the congenital form of the disorder.
These 3 mRNAs likely represent only a small subset of
the transcripts mis-spliced in neurons in this disease. The
identity of these additional mRNAs will be critical for un-
derstanding the effects of DM1 on the nervous system in
adults and children.
Given the complexity of RNA splicing and process-
ing in neurons, it is perhaps not surprising that all of the
RNA-dominant disorders uncovered to date have some
central nervous system effects, although the specific effects
are highly variable between the disorders, and more subtle
in some than others. The exact effect of each repeat ex-
pansion on splicing and RNA processing in specific cell
types and regions in the brain at least partially explains
how a single mechanism can lead to such different phe-
notypes across these diseases. However, exactly what
drives the disease and tissue specificity of neurodegenera-
tion in RNA-dominant diseases (and protein mediated
neurodegenerative diseases, for that matter) remains
largely unknown.
Antisense Transcripts and Aberrant
Transcriptional Regulation
One of the most intriguing recent developments in repeat
expansion disorders is the emerging role of antisense tran-
scripts in disease pathogenesis (Fig 2). As discussed above,
antisense transcripts are very common in the genome and
likely play important roles in RNA stability and transcrip-
tional activity. A role for toxicity associated with these
transcripts is best established for spinocerebellar ataxia
type 8 (SCA8). In this disorder, a CTG repeat expansion
in a nonprotein coding gene is associated with disease.
Normal individuals typically have upward of 50 repeats,
whereas patients with SCA8 typically have between 70
and 250 repeats. This CTG repeat is transcribed as
FIGURE 2: Transcriptional dysregulation and antisense transcripts in repeat expansion diseases. In addition to effects on
RNA splicing, expanded noncoding nucleotide repeats likely lead to neurodegeneration via a number of overlapping mech-
anisms. (A) At the level of DNA, the repeats themselves may impact both the temporal expression (as in congenital
myotonic dystrophy) and the level of expression of the expanded repeat containing mRNAs (as in fragile X tremor ataxia
syndrome) by altering local chromatin structure. (B) In many cases, antisense transcripts through the repeat sequence are
also produced. These antisense transcripts may be translated into poly-amino acid-containing proteins (eg, polyglutamine
proteins in spinocerebellar ataxia type 8), elicit toxicity directly at the RNA level, or both. They also may play a role in
regulating the stability of the expanded repeat-containing sense transcripts.
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Ataxin8OS (ataxin-8 opposite strand), a noncoding
mRNA expressed in the brain and cerebellum.31 Initial
work on SCA8 suggested that this CTG repeat acts via a
dominant mechanism at the mRNA level similar to that
seen in DM1.32 In line with this hypothesis, a recent
study demonstrates mis-splicing of a GABA tranporter in
the cerebellum in SCA8 that is dependent on sequestra-
tion of MBNL1 and results in cerebellar dysfunction.33
However, there is also evidence that an antisense tran-
script is produced that includes the expansion.34 This
transcript contains a short open reading frame that would
translate the repeat in the CAG direction into an ex-
panded polyglutamine polypeptide. Moreover, nuclear in-
clusions of aggregated protein that immunostain for poly-
glutamine have been noted in the cerebellum of an SCA8
patient. It remains unclear, however, if this CAG tran-
script and resultant polyglutamine protein contribute sig-
nificantly to SCA8 pathogenesis.
A similar mixed mechanism may be present in Hun-
tington disease-like 2 (HDL2). HDL2 is a rare disorder
clinically similar to Huntington disease that results from a
CTG repeat expansion in the Junctophilin-3 gene. Patho-
logic samples from patients with HDL2 demonstrate neu-
rodegeneration in the striatum and the formation of RNA
foci that contain expanded CUG repeat sequences and
MBNL1.35,36 However, these same pathologic samples
demonstrate ubiquitin-positive inclusions that stain for
the presence of a polyglutamine protein.36 Thus, an anti-
sense transcript encoding for a glutamine stretch may also
be present in this disorder and contribute to pathogenesis.
In addition to possibly encoding toxic proteins, an-
tisense transcripts also have potential roles in modifying
RNA stability of the toxic mRNA product. Two different
antisense transcripts have been described in FXTAS, 1 of
which begins in the first exon (ASFMR1) and extends
through the CGG:CCG repeat with multiple splice vari-
ants, the other of which overlaps only the very 5 end of
the sense transcript start site (FMR4).37,38 At least 1 iso-
form of ASFMR1 contains an open reading frame that
would be predicted to lead to translation of a polyproline-
containing protein through the CCG repeat sequence, but
to date there is no evidence that this actually occurs.
However, these transcripts potentially play important
roles in RNA toxicity and in the stability of the sense
transcript. Along this line, 1 intriguing experiment in a fly
model of FXTAS demonstrated that expression of a CGG
or CCG repeat mRNA can induce toxicity in flies, but
that coexpression of both mRNAs leads to phenotypic
rescue via an Argonaute 2 (ie, RNA interference)-
dependent pathway.39 In lymphoblasts derived from
FXTAS patients, both the sense and antisense FMR1
transcripts are upregulated in cells, but toxicity could re-
sult from an imbalance of sense and antisense mRNA ex-
pression levels in affected tissues.
The expanded nucleotide repeats also have impor-
tant effects in cis at the gene level. In FXTAS, the ex-
panded CGG repeat may contribute directly to increased
transcription of the FMR1 mRNA by effecting local chro-
matin structure.40,41 Similarly, the more severe phenotype
seen in congenital DM1 may result not only from a larger
CTG expansion at the mRNA level, but also from effects
of the CTG expansion on local chromatin regulation and
transcription, both of itself and of surrounding genes. In
congenital DM1, unlike adult DM1, the DMPK locus be-
comes methylated. This methylation inhibits CTCF bind-
ing at sites surrounding the DMPK gene, leading to tran-
scriptional activation of DMPK concurrent with that of a
nearby homeodomain gene, Six5.42 As Six5 is expressed at
high levels during early neuronal and muscular develop-
ment,43 temporally aberrant expression of toxic DMPK
mRNA could lead to a developmental phenotype that
would be absent in adult onset DM1. However, this hy-
pothesis has not yet been tested in vivo.
In addition to altered mRNA splicing, significant ef-
fects on the transcriptional regulation of many other
genes have also been reported for both FXTAS and
DM1.44,45 In DM1, some of these changes may still be
explained by sequestration of MBNL1, although it re-
mains unclear if this reflects a direct role of MBNL1 in
transcriptional regulation or an indirect effect through al-
tered splicing of critical transcription factors.44 In
FXTAS, some of these effects may be mediated by Pur ,
which can act as a transcriptional repressor.46,47
Cellular and Protein Homeostasis in RNA-
Mediated Disease
The culmination of the diverse pathogenic mechanisms
discussed above is neuronal dysfunction and death. The
degree of mechanistic overlap between mRNA and
protein-mediated disorders is unknown, but early evi-
dence suggests some commonality in these neurodegen-
erative pathways. For example, the intranuclear inclusions
in FXTAS contain many proteins that are not thought to
interact directly with mRNA, including nuclear lamin
proteins that function in nuclear envelope formation and
structure. Intriguingly, the nuclear envelope structure in
cultured cells transfected with an expanded CGG repeat
mRNA is abnormal.48 Beyond sequestration of specific
proteins, the biological impact of inclusions is also un-
clear. The inclusions in FXTAS are ubiquitinated, and
both the neuronal inclusions in FXTAS and the RNA foci
in DM1 contain components of the proteasome.28,49 In
addition, overexpression of chaperone proteins (eg, HSP-
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70) alleviates aspects of the FXTAS phenotype in a dro-
sophila model, and cells overexpressing an expanded CGG
repeat-containing mRNA display increased sensitivity to
impairment of the ubiquitin-proteasome system.45,50
These results support a model of disease in which aber-
rant mRNA-protein interactions can lead to degradation-
resistant complexes that may function as a toxic species in
these disorders, interfering with a host of cellular pro-
cesses in a manner similar to that proposed for polyglu-
tamine proteins.
RNA Toxicity in Polyglutamine Disorders
Until recently, mRNA transcripts were not thought to con-
tribute significantly to toxicity in repeat expansion disor-
ders where the repeat is translated into protein. However, a
recent experiment questions this dogma for at least some
polyglutamine disorders. Spinocerebellar ataxia type 3, also
known as Machado-Joseph disease, results from a CAG ex-
pansion that encodes an abnormally long polyglutamine
stretch in the disease protein, ataxin-3. Using a genetic
modifier screen in a drosophila model of SCA3, Li et al
found that the muscleblind protein family implicated in
DM1 pathogenesis also modified the ataxin-3 expanded re-
peat phenotype.51 Modification of the mRNA sequence
from a pure CAG repeat to CAACAG (which still encodes
glutamine) reduced the toxicity of the repeat in flies, de-
spite similar expression of the polyglutamine protein.
Moreover, expression of a long, untranslatable CAG repeat
by itself in the 3UTR of a reporter gene caused slowly
progressive neurodegeneration. This neurodegeneration did
not appear to be due to transcription of an antisense CUG-
containing mRNA. Taken together, these findings suggest
that large CAG repeats could contribute to disease pro-
cesses at the mRNA level in some polyglutamine disorders.
However, whether these findings are relevant to mamma-
lian systems and patients with polyglutamine disorders is
still unknown. Given the requirement for very large repeats
to achieve toxicity in the drosophila model system, it will
likely only be significant in humans if there is dramatic
somatic repeat instability in affected tissues. This possibility
needs to be investigated.
In some polyglutamine disorders, however, it seems
unlikely that mRNA-mediated neurodegeneration plays a
prominent role. For example, in spinal and bulbar mus-
cular atrophy (also known as Kennedy disease), a patho-
genic expanded CAG repeat that is translated into a poly-
glutamine tract is present in the androgen receptor gene.
There is clear evidence from drosophila and mouse models
that translocation of the disease protein to the nucleus in
response to ligand binding is required for disease patho-
genesis, precluding a primary role for mRNA toxicity.52
Moreover, single nonconservative nucleotide changes dis-
tant from the CAG repeat sequence in Atxn1, the disease
gene in spinocerebellar ataxia type 1, can abrogate toxicity
in a mouse model of the disease without affecting mRNA
levels.53 Lastly, an earlier study that formally tested for
toxicity from untranslated CAG repeats failed to show an
effect, although the expansion size of the tested repeat was
smaller.54 Thus, further research is needed to determine
the impact of this finding that very long CAG repeats can
lead to RNA-mediated toxicity in polyglutamine disor-




As RNA-mediated disorders do not change the sequence or
function of the protein associated with the mutated gene,
they may be particularly amenable to curative therapeutic
development. Moreover, in DM1 in particular, there is
fairly strong evidence that haploinsufficiency for the associ-
ated protein, DMPK, is not associated with significant dys-
function in animal models. Thus, therapeutics targeted at
the elimination of the toxic mRNA hold great promise (Fig
3). Two recent papers using antisense technology in animal
models of DM1 have provided proof of principal for this
technique. In the first of these, Wheeler et al used a mor-
pholino synthetic oligonucleotide made up of 8 CAG re-
peats to interfere with the interaction of the expanded
CUG repeat containing mRNA and MBNL1 in a mouse
model of DM1.55 Delivery of this morpholino into affected
muscles led to elimination of RNA foci, correction of splic-
ing abnormalities, and a reversal of clinical myotonia. In a
second related paper, Mulders et al utilized a modified an-
tisense oligonucleotide in two mouse models of DM1 and
also demonstrated resolution of RNA foci and splicing ab-
normalities, although myotonia persisted.56 Importantly,
nonspecific toxicity was not observed in either study.
A second line of therapeutic development involves
identification of small molecules that directly interfere
with the interaction of expanded nucleotide repeats and
their connate RNA-binding protein partners. Three dif-
ferent groups have used various rational compound
screening approaches to identify molecules as inhibitors of
the interaction of expanded CUG repeats with
MBNL1.57–59 Warf et al have gone on to demonstrate
that their identified compound, pentamidine, is capable
of reversing splicing defects in cell culture and in a mouse
model of DM1.58 Similar chemical studies have also been
done to target CAG and CCUG mRNA repeats, suggest-
ing that this technique may have broader application to
all RNA-dominant disorders.59,60 Other recent studies
have utilized high-throughput drug screens in either cell
culture or invertebrate models of DM1. A recent screen in
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a drosophila model of DM1 identified 10 compounds,
most of which have been approved by the US Food and
Drug Administration for other indications, that suppress
CUG RNA toxicity.61
Conclusions and Future Directions
It is now clear that mRNA plays a primary pathogenic
role in several disorders that involve the central nervous
system. Moreover, this toxicity is probably mediated via
several parallel mechanisms, including sequestration of
RNA-splicing factors and RNA-binding proteins, altered
production of coding and noncoding antisense transcripts
that themselves exert deleterious consequences at multiple
levels, and accumulation of mRNA/protein aggregates
that may have detrimental effects on cellular homeostasis.
If anything, these multiple mechanisms are likely to be-
come more complicated in the next few years, as explora-
tions of the roles played by microRNAs and other non-
coding RNAs are considered in these diseases. Sorting out
which mechanistic components are critical mediators of
toxicity in each disorder will be required to understand
the pathogenesis of these diseases. Yet, based on our un-
derstanding of these mechanisms to date, early preclinical
studies aimed at eliminating or neutralizing the toxic
mRNA species are raising hope that therapeutic ap-
proaches to these diseases will be available for clinical ap-
plication in the not too distant future.
This work was supported by a Clinical Research Training
Fellowship from the American Academy of Neurology
(P.K.T.) and the NIH NINDS (RO1 NS 38712; H.L.P.,
principal investigator).
We thank C. Thornton and V. Shakkottai for critical
reading of the manuscript.
References
1. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein
misfolding revisited. Trends Neurosci 2008;31:521–528.
2. O’Rourke JR, Swanson MS. Mechanisms of RNA-mediated dis-
ease. J Biol Chem 2009;284:7419–7423.
3. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol
Genet 2006;15 Spec No 2:R162–R169.
4. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;
136:777–793.
5. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders.
Annu Rev Neurosci 2006;29:259–277.
6. Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS
about TDP-43. Cell 2009;136:1001–1004.
7. Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in
transgenic mice expressing an expanded CUG repeat. Science
2000;289:1769–1773.
8. de Haro M, Al-Ramahi I, De Gouyon B, et al. MBNL1 and
CUGBP1 modify expanded CUG-induced toxicity in a Drosophila
model of myotonic dystrophy type 1. Hum Mol Genet 2006;15:
2138–2145.
9. Taneja KL, McCurrach M, Schalling M, et al. Foci of trinucle-
otide repeat transcripts in nuclei of myotonic dystrophy cells
and tissues. J Cell Biol 1995;128:995–1002.
10. Miller JW, Urbinati CR, Teng-Umnuay P, et al. Recruitment of
human muscleblind proteins to (CUG)(n) expansions associated
with myotonic dystrophy. EMBO J 2000;19:4439–4448.
11. Kanadia RN, Shin J, Yuan Y, et al. Reversal of RNA missplicing
and myotonia after muscleblind overexpression in a mouse poly-
FIGURE 3: Therapeutic development in RNA-mediated diseases. Recent studies support at least 2 therapeutic approaches to
RNA-dominant diseases. (A) Eliminating the toxic RNA hairpin structure can be achieved using short antisense oligonucle-
otide transcripts. Depending on how they are constructed, the oligonucleotides can either lead to the degradation of the
toxic RNA or interfere with the formation of the hairpin structure that is thought to elicit toxicity. (B) Small molecules can
be used to interfere directly with the interaction between toxic RNA and its binding proteins. Both treatments free the
sequestered RNA-binding proteins to perform their normal functions, thus restoring RNA-processing homeostasis.
ANNALS of Neurology
298 Volume 67, No. 3
(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A
2006;103:11748–11753.
12. Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind
knockout model for myotonic dystrophy. Science 2003;302:
1978–1980.
13. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type
2 caused by a CCTG expansion in intron 1 of ZNF9. Science
2001;293:864–867.
14. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of
the fragile X-associated tremor/ataxia syndrome in a premutation
carrier population. JAMA 2004;291:460–469.
15. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of
FMR1 mRNA in carrier males: a new mechanism of involvement
in the fragile-X syndrome. Am J Hum Genet 2000;66:6–15.
16. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement
and protein expression in individuals with the FMR1 premutation.
Am J Med Genet 2000;91:144–152.
17. Jin P, Duan R, Qurashi A, et al. Pur alpha binds to rCGG repeats
and modulates repeat-mediated neurodegeneration in a Dro-
sophila model of fragile X tremor/ataxia syndrome. Neuron 2007;
55:556–564.
18. Sofola OA, Jin P, Qin Y, et al. RNA-binding proteins hnRNP
A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-
induced neurodegeneration in a Drosophila model of FXTAS.
Neuron 2007;55:565–571.
19. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing reg-
ulated by a CUG-binding protein in myotonic dystrophy. Science
1998;280:737–741.
20. Charlet BN, Savkur RS, Singh G, et al. Loss of the muscle-
specific chloride channel in type 1 myotonic dystrophy due to
misregulated alternative splicing. Mol Cell 2002;10:45–53.
21. Wang GS, Kearney DL, De Biasi M, et al. Elevation of RNA-
binding protein CUGBP1 is an early event in an inducible heart-
specific mouse model of myotonic dystrophy. J Clin Invest 2007;
117:2802–2811.
22. Orengo JP, Chambon P, Metzger D, et al. Expanded CTG re-
peats within the DMPK 3’ UTR causes severe skeletal muscle
wasting in an inducible mouse model for myotonic dystrophy.
Proc Natl Acad Sci U S A 2008;105:2646–2651.
23. Timchenko NA, Iakova P, Cai ZJ, et al. Molecular basis for im-
paired muscle differentiation in myotonic dystrophy. Mol Cell
Biol 2001;21:6927–6938.
24. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-
state levels of CUGBP1 in myotonic dystrophy 1 are due to
PKC-mediated hyperphosphorylation. Mol Cell 2007;28:68–78.
25. Tian B, White RJ, Xia T, et al. Expanded CUG repeat RNAs form
hairpins that activate the double-stranded RNA-dependent pro-
tein kinase PKR. RNA 2000;6:79–87.
26. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG
repeats trigger aberrant splicing of ClC-1 chloride channel
pre-mRNA and hyperexcitability of skeletal muscle in myotonic
dystrophy. Mol Cell 2002;10:35– 44.
27. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1
splicing eliminates chloride channelopathy and myotonia in
mouse models of myotonic dystrophy. J Clin Invest 2007;117:
3952–3957.
28. Jiang H, Mankodi A, Swanson MS, et al. Myotonic dystrophy
type 1 is associated with nuclear foci of mutant RNA, seques-
tration of muscleblind proteins and deregulated alternative splic-
ing in neurons. Hum Mol Genet 2004;13:3079–3088.
29. Gomes-Pereira M, Foiry L, Nicole A, et al. CTG trinucleotide
repeat “big jumps”: large expansions, small mice. PLoS Genet
2007;3:e52.
30. Sergeant N, Sablonniere B, Schraen-Maschke S, et al. Dysregu-
lation of human brain microtubule-associated tau mRNA matura-
tion in myotonic dystrophy type 1. Hum Mol Genet 2001;10:
2143–2155.
31. Koob MD, Moseley ML, Schut LJ, et al. An untranslated CTG
expansion causes a novel form of spinocerebellar ataxia (SCA8).
Nat Genet 1999;21:379–384.
32. Mutsuddi M, Marshall CM, Benzow KA, et al. The spinocerebellar
ataxia 8 noncoding RNA causes neurodegeneration and associ-
ates with staufen in Drosophila. Curr Biol 2004;14:302–308.
33. Daughters RS, Tuttle DL, Gao W, et al. RNA gain-of-function in
spinocerebellar ataxia type 8. PLoS Genet 2009;5:e1000600.
34. Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of
CUG and CAG expansion transcripts and intranuclear polyglu-
tamine inclusions in spinocerebellar ataxia type 8. Nat Genet
2006;38:758–769.
35. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington’s disease-
–like 2 is associated with CUG repeat-containing RNA foci. Ann
Neurol 2007;61:272–282.
36. Rudnicki DD, Pletnikova O, Vonsattel JP, et al. A comparison of
Huntington disease and Huntington disease-like 2 neuropathol-
ogy. J Neuropathol Exp Neurol 2008;67:366–374.
37. Ladd PD, Smith LE, Rabaia NA, et al. An antisense transcript
spanning the CGG repeat region of FMR1 is upregulated in
premutation carriers but silenced in full mutation individuals.
Hum Mol Genet 2007;16:3174 –3187.
38. Khalil AM, Faghihi MA, Modarresi F, et al. A novel RNA tran-
script with antiapoptotic function is silenced in fragile X syn-
drome. PLoS One 2008;3:e1486.
39. Sofola OA, Jin P, Botas J, Nelson DL. Argonaute-2-dependent
rescue of a Drosophila model of FXTAS by FRAXE premutation
repeat. Hum Mol Genet 2007;16:2326–2332.
40. Mulvihill DJ, Nichol Edamura K, Hagerman KA, et al. Effect of
CAT or AGG interruptions and CpG methylation on nucleosome
assembly upon trinucleotide repeats on spinocerebellar ataxia,
type 1 and fragile X syndrome. J Biol Chem 2005;280:
4498–4503.
41. Wang YH, Gellibolian R, Shimizu M, et al. Long CCG triplet
repeat blocks exclude nucleosomes: a possible mechanism for
the nature of fragile sites in chromosomes. J Mol Biol 1996;263:
511–516.
42. Filippova GN, Thienes CP, Penn BH, et al. CTCF-binding sites
flank CTG/CAG repeats and form a methylation-sensitive insula-
tor at the DM1 locus. Nat Genet 2001;28:335–343.
43. Fougerousse F, Durand M, Lopez S, et al. Six and Eya expres-
sion during human somitogenesis and MyoD gene family activa-
tion. J Muscle Res Cell Motil 2002;23:255–264.
44. Osborne RJ, Lin X, Welle S, et al. Transcriptional and post-
transcriptional impact of toxic RNA in myotonic dystrophy. Hum
Mol Genet 2009;18:1471–1481.
45. Handa V, Goldwater D, Stiles D, et al. Long CGG-repeat tracts
are toxic to human cells: implications for carriers of Fragile X
premutation alleles. FEBS Lett 2005;579:2702–2708.
46. Chen NN, Khalili K. Transcriptional regulation of human JC poly-
omavirus promoters by cellular proteins YB-1 and Pur alpha in
glial cells. J Virol 1995;69:5843–5848.
47. Shelley CS, Da Silva N, Teodoridis JM. During U937 monocytic
differentiation repression of the CD43 gene promoter is medi-
ated by the single-stranded DNA binding protein Pur alpha. Br J
Haematol 2001;115:159–166.
48. Arocena DG, Iwahashi CK, Won N, et al. Induction of inclusion
formation and disruption of lamin A/C structure by premutation
CGG-repeat RNA in human cultured neural cells. Hum Mol
Genet 2005;14:3661–3671.
49. Iwahashi CK, Yasui DH, An HJ, et al. Protein composition of the
intranuclear inclusions of FXTAS. Brain 2006;129:256–271.
Todd and Paulson: RNA Mediated Neurodegeneration
March, 2010 299
50. Jin P, Zarnescu DC, Zhang F, et al. RNA-mediated neurodegen-
eration caused by the fragile X premutation rCGG repeats in
Drosophila. Neuron 2003;39:739–747.
51. Li LB, Yu Z, Teng X, Bonini NM. RNA toxicity is a component of
ataxin-3 degeneration in Drosophila. Nature 2008;453:
1107–1111.
52. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction
prevents phenotypic expression in a transgenic mouse model of
spinal and bulbar muscular atrophy. Neuron 2002;35:843–854.
53. Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1
is critical for polyglutamine-induced disease in SCA1 transgenic
mice. Neuron 2003;38:375–387.
54. McLeod CJ, O’Keefe LV, Richards RI. The pathogenic agent in
Drosophila models of ’polyglutamine’ diseases. Hum Mol Genet
2005;14:1041–1048.
55. Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA dom-
inance by displacement of protein sequestered on triplet repeat
RNA. Science 2009;325:336–339.
56. Mulders SA, van den Broek WJ, Wheeler TM, et al. Triplet-
repeat oligonucleotide-mediated reversal of RNA toxicity in myo-
tonic dystrophy. Proc Natl Acad Sci U S A 2009;106:
13915–13920.
57. Arambula JF, Ramisetty SR, Baranger AM, Zimmerman SC. A
simple ligand that selectively targets CUG trinucleotide repeats
and inhibits MBNL protein binding. Proc Natl Acad Sci U S A
2009;106:16068–16073.
58. Warf MB, Nakamori M, Matthys CM, et al. Pentamidine reverses
the splicing defects associated with myotonic dystrophy. Proc
Natl Acad Sci U S A 2009;106:18551–18556.
59. Pushechnikov A, Lee MM, Childs-Disney JL, et al. Rational de-
sign of ligands targeting triplet repeating transcripts that cause
RNA dominant disease: application to myotonic muscular dystro-
phy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc
2009;131:9767–9779.
60. Lee MM, Pushechnikov A, Disney MD. Rational and modular de-
sign of potent ligands targeting the RNA that causes myotonic
dystrophy 2. ACS Chem Biol 2009;4:345–355.
61. Garcia-Lopez A, Monferrer L, Garcia-Alcover I, et al. Genetic and
chemical modifiers of a CUG toxicity model in Drosophila. PLoS
One 2008;3:e1595.
ANNALS of Neurology
300 Volume 67, No. 3
